10.1038/s41375-020-0840-y - Upregulation of CD38 expression on mu...

This document has been corrected

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab

10.1038/s41375-020-0840-y

Published Online: 2020-04-29

Journal: Leukemia•Publisher: Springer Science and Business Media LLC

Authors: Alfonso Rodríguez-Gil•Estefanía García-Guerrero•Hermann Einsele•José A. Pérez-Simón•K. Martin Kortüm•Markus Sauer•Michael Hudecek•Ralph Götz•Sophia Danhof•Sören Doose•Thomas Nerreter

This document has been corrected

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab

10.1038/s41375-020-0840-y

Published Online: 2020-04-29

Journal: Leukemia

NOW

2021-11-29•Correction

Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab

10.1038/s41375-021-01355-6

* information provided by CrossRef

2021-11-29•Correction

10.1038/s41375-021-01355-6

* information provided by CrossRef

2020-04-29•Published

2021-11-29•Correction

Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab

10.1038/s41375-021-01355-6

* information provided by CrossRef

This document has been corrected

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab

10.1038/s41375-020-0840-y

Published Online: 2020-04-29

Journal: Leukemia•Publisher: Springer Science and Business Media LLC